Theranos’s Reviewers Find Solutions To Existing Glitches

For many people who are not in tech the name Theranos doesn’t really hold any significance yet, but it will most likely for you some day. This little startup has amassed seed money in the multi-billion dollar range and has investors willing to hemorrhage into them for the foreseeable future given the value of this initial investment. The problem with this company is that despite all of the infrastructure and strength of their ideas, The problem is the one thing they are lacking, which is the one thing in regards to the future of the medical industry is Data. data is at the heart of this entire show and if you do not have a platform that understands this you are going to be left in the dust.

Luckily the bioinformation research group from the Icahn institue of Mount Sinai medical group has published the high level results of a study they’ve been working on for about a year. They put Theranos in their cross hairs and the results are actually, not as bad as some may have been thinking, in fact they are actually in some regards down right good. The tests were conducted by recruiting 60 healthy patients for a gauntlet of 22 tests to compare the accuracy of blood tests that were obtained from a single finger prick via Theranos’s tech, with a standard draw from conventional test companies Quest and LabCorp. It is not uncommon to have the experts step in, in this way.

At the base level the findings did not appear to be good for Theranos when considering what it espoused of doing. Of the 3 vendors conducting these tests, it had the highest number of results actually. This was outside the normal range according to the LabCorp spokesperson.

A Theranos Spokesperson did not respond to these concerns immediately and the myriad request for comments because it was unclear what they even told them about themselves and the direction of the industry in general.

This is not to say however that they did not immediately question the researchers methodology and accuracy of their test, even an okay finish in both tech and medical fields are potentially coffin nails. But one particular point of contention was that by taking a dose of blow from the vein immediately before you prick the finger, which is what they were doing in the Icahn researches test, is considered standard practice although, ineffective. But the spokesman Dudley says they took this approach to mimic a real world scenario, where in a patient might get multiple blood tests a day. Their point this did affect the test as they wanted it in a kind of vacuum, but it is important to remember that the patients are people and this product needs to be considered in how it will work in the homes of the affected individuals and not in a sterile test facility. That said there is hope that these problems will be rectified. However, Dudley maintains that he is disappointed by the reaction, and that he was expecting them to respond by publishing their own data.